Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

8 April 2020Regulatory
Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual

31 March 2020Company News, Regulatory
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation modes: nebulizer, DPI and pMDI Initiation of multiple dose part of pMDI trial postponed due to the

20 March 2020Regulatory
Verona Pharma plc: Issue of Equity and Total Voting Rights

LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it yesterday issued 887,080 Ordinary Shares of 5

16 March 2020Regulatory
2019 Annual Report and Accounts and Notice of AGM

LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and

5 March 2020Regulatory
Grant of Restricted Stock Units and PDMR Dealings

LONDON, March 05, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 3, 2020, it granted

27 February 2020Regulatory
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT LONDON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2020. All rights reserved